$11.78
0.60% yesterday
Nasdaq, Jul 02, 10:00 pm CET
ISIN
US1266381052
Symbol
CVRX

CVRx Inc Share price

$11.78
+5.07 75.56% 1M
-18.71 61.36% 6M
-19.66 62.53% YTD
-3.62 23.51% 1Y
-13.68 53.73% 3Y
-16.22 57.93% 5Y
-16.22 57.93% 10Y
Nasdaq, Closing price Tue, Jul 02 2024
+0.07 0.60%
ISIN
US1266381052
Symbol
CVRX
Sector

Key metrics

Market capitalization $254.40m
Enterprise Value $204.88m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.87
P/S ratio (TTM) P/S ratio 6.04
P/B ratio (TTM) P/B ratio 3.84
Sales growth (TTM) Sales growth 59.59%
Turnover (TTM) Turnover $42.09m
EBIT (operating result TTM) EBIT $-53.17m
Free cash flow (TTM) Free cash flow $-40.94m
Cash position $80.12m
EPS (TTM) EPS $-2.48
P/E ratio expected negative
P/S ratio expected 5.01
EV/Sales expected 4.03
Short interest 11.76%
Show more

Is CVRx Inc a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.

CVRx Inc Share analysis

Unlock Scores for Free

Analyst opinions

6 Analysts have issued a CVRx Inc forecast:

4x Buy
67%
2x Hold
33%

Analyst opinions

6 Analysts have issued a CVRx Inc forecast:

Buy
67%
Hold
33%

Financial data from CVRx Inc

Assets
Dec '23
112 112
Cash position 91 91
Claims 7.55 7.55
Inventories 11 11
Other current assets Other current assets Current assets 2.99 2.99
3.14 3.14
Property, plant and equipment 3.11 3.11
Financial assets - -
Intangible assets - -
Other fixed assets Other assets Fixed assets 0.03 0.03
Total assets 115 115
Liabilities
Dec '23
Equity 76 76
39 39
Current liabilities 7.86 7.86
Non-current liabilities 31 31
Total capital 115 115

Figures in millions USD.

Don't miss a thing! We will send you all news about the CVRx Inc share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

CVRx Inc Share News

Neutral
GlobeNewsWire
8 days ago
MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointment of Robert John as Chief Revenue Officer effective June 27. In this role, John will lead the Company's US sales team with the objective of maximizing the positive impact of Barostim therapy on patients suffering from heart failure and estab...
Neutral
Accesswire
24 days ago
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ:CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
PRNewsWire
26 days ago
NEW YORK , June 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
More CVRx Inc News

Company profile

CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. It has developed the second generation Barostim neo, an implantable system designed to treat heart failure and hypertension. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2000 and is headquartered in Minneapolis, MN.

Head office United States
CEO Kevin Hykes
Employees 200
Founded 2001
Website www.cvrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today